IFNG and cancer: A total of six immune subtype were compared with YTHDC2 expression across diverse cancers, including C1 (wound healing), C2 (IFN‐gamma dominant), C3 (inflammatory), C4 (lymphocyte depleted), C5 (immunologically quiet) and C6 (TGF‐b dominant), and YTHDC2 was notably associated with immune subtypes of nine cancer types, including BLCA, BRCA, KIRC, LIHC, LUAD, PAAD, SKCM, STAD and UCEC (Figure S4).